Epygenix Therapeutics is currently engaged in pivotal clinical studies for Dravet syndrome and Lennox-Gastaut syndrome. Our goal is to develop safe and effective treatment for these intractable epilepsies.
Epygenix is currently running a single privatol study for Dravet syndrome patients with EPX-100.
Epygenix Therapeutics focuses on development of new treatments for rare and catastrophic forms of genetic epilepsy, including Dravet Syndrome, Lennox-Gastaut Syndrome, Ohtahara Syndrome, and other rare genetic epilepsies.
Our technology is based on pioneering zebrafish epilepsy models and drug screening developed at the University of California, San Francisco. This unique approach combines first-in-class modeling of genetic epilepsies with high-throughput phenotype-based drug screening.
What is Epygenix?
Epygenix Therapeutics is a clinical stage biopharmaceutical company developing drugs to treat Dravet syndrome (DS) and other genetic epilepsies. DS is a rare and catastrophic form of intractable epilepsy that begins in infancy. Current therapeutic options are not sufficient, and the constant care required can severely impact the quality of life for the entire family.